Cargando…

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide

Glypican-3 (GPC3), which is a carcinoembryonic antigen, is overexpressed in human hepatocellular carcinoma (HCC). Previously, we performed a phase I clinical trial of GPC3-derived peptide vaccination in patients with advanced HCC, and reported that GPC3 peptide vaccination is safe and has clinical e...

Descripción completa

Detalles Bibliográficos
Autores principales:	TADA, YOSHITAKA, YOSHIKAWA, TOSHIAKI, SHIMOMURA, MANAMI, SAWADA, YU, SAKAI, MAYUKO, SHIRAKAWA, HIROFUMI, NOBUOKA, DAISUKE, NAKATSURA, TETSUYA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 201
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829797/ https://www.ncbi.nlm.nih.gov/pubmed/23903757 http://dx.doi.org/ 10.3892/ijo.2013.2044

Ejemplares similares

Identification of an H2-K(b) or H2-D(b) restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide
por: IWAMA, TATSUAKI, et al.
Publicado: (2013)

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2016)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes
por: Akazawa, Yu, et al.
Publicado: (2019)

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
por: SAWADA, YU, et al.
Publicado: (2014)

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case
por: Sawada, Yu, et al.
Publicado: (2013)

Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy
por: Nobuoka, Daisuke, et al.
Publicado: (2012)

A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
por: OFUJI, KAZUYA, et al.
Publicado: (2014)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

Peptide vaccines for hepatocellular carcinoma
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Next-Generation Cancer Immunotherapy Targeting Glypican-3
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Identification of a novel HLA-A(*)02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene
por: YOSHIMURA, MAYUKO, et al.
Publicado: (2014)

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3
por: Kawashima, Issei, et al.
Publicado: (2015)

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model
por: Fujinami, Norihiro, et al.
Publicado: (2016)

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
por: SUGAI, SHIORI, et al.
Publicado: (2016)

Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis
por: Taniguchi, Masatake, et al.
Publicado: (2020)

Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer
por: Akazawa, Yu, et al.
Publicado: (2020)

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports
por: Suzuki, Shiro, et al.
Publicado: (2014)

Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy
por: YOSHIKAWA, TOSHIAKI, et al.
Publicado: (2014)

Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus
por: YABUSAKI, MINA, et al.
Publicado: (2014)

Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response
por: Sayem, Mohammad A., et al.
Publicado: (2015)

Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances
por: Charneau, Jimmy, et al.
Publicado: (2021)

Time-lapse imaging assay using the BioStation CT: A sensitive drug-screening method for three-dimensional cell culture
por: Sakamoto, Ruriko, et al.
Publicado: (2015)

Plasma and tumoral glypican‐3 levels are correlated in patients with hepatitis C virus‐related hepatocellular carcinoma
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma
por: Suzuki, Shiro, et al.
Publicado: (2016)

Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma
por: Ukai, Mayu, et al.
Publicado: (2021)

Neuroendocrine Tumors Show Altered Expression of Chondroitin Sulfate, Glypican 1, Glypican 5, and Syndecan 2 Depending on Their Differentiation Grade
por: García-Suárez, Olivia, et al.
Publicado: (2014)

Glypicans
por: Filmus, Jorge, et al.
Publicado: (2008)

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
por: Sawada, Yu, et al.
Publicado: (2016)

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2014)

Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery
por: Miura, Masahiro, et al.
Publicado: (2020)

Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer
por: SAWADA, YU, et al.
Publicado: (2014)

Adnectin–drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors
por: Lipovšek, Daša, et al.
Publicado: (2018)

Efficacy of the NCCV Cocktail‐1 vaccine for refractory pediatric solid tumors: A phase I clinical trial
por: Akazawa, Yu, et al.
Publicado: (2019)

Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma
por: Li, Kesang, et al.
Publicado: (2015)

Greater extent of blood‐tumor TCR repertoire overlap is associated with favorable clinical responses to PD‐1 blockade
por: Aoki, Hiroyasu, et al.
Publicado: (2021)

Development of antigen‐prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse
por: Charneau, Jimmy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3p4932q4jdtf63uif23cgs1fr6